To investigate the impact of tumor-intrinsic PSMB9 expression on CD19 CAR-T cell therapy, we first examined PSMB9 protein levels across CD19+ ALL cell line Nalm6 and lymphoma cell lines Raji and Daudi using Western blot analysis. The gene discussed is PSMB9; the disease is neoplasm.